NCT05986162尚未招募1 期
A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Clinical Activity of Itolizumab in Subjects With Dermatomyositis
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 44
- 主要终点
- Incidence of Treatment Emergent Adverse Events
研究概览
简要总结
To evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of Itolizumab in subjects with Dermatomyositis.
详细描述
The study will enroll approximately 44 subjects in two parts:
Part 1 is an open label, 3+3 single dose escalation and then mutiple dose administration phase. 9~30 patients with DM are expected to be enrolled across 3 dose cohorts.
Part 2 is a randomized phase and will enroll approximately 14 additional subjects, randomized in a 1:1 ratio to one of the 2 doses based on efficacy data obtained from Part 1. All participants in this study will receive Itolizumab intravenously every two weeks for a total of 7 doses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subject aged 18-75 years old (inclusive).
- •Fulfill one of the following criteria for DM:1) Bohan and Peter criteria for definite or probable DM;2) ENMC 2018 Dermatomyositis Classification Criteria
- •Disease activity fulfills at least three of the following criteria:1) MMT-8 score < 142; 2) physician's global disease activity ≥2 cm; 3) patient's global activity ≥2 cm; 4) extra-muscular activity ≥2 cm; 5) Health Assessment Questionnaire [HAQ] ≥0.25; 6) at least one muscle enzyme >1.5 times ULN
- •Under treatment with corticosteroids and/or at least 1 immunesuppressant, and being on stable therapy for at least 4 and 8 weeks for corticosteroids and immunesuppressant respectively (see Section 5.7.1)
- •Fulfill all of the following criteria: 1) % predicted values of FVC≥70%; 2) % predicted values of DLCO≥60%; 3) chest HRCT indicating the extent of disease lesion of DM-ILD < 20% as determined by the investigator
- •Negative result of serum HCG within 72 hours before enrollment for female with potential fertility
- •Able to understand and comply with the planned procedure as required by the protocol, and sign a written informed consent form (ICF)
排除标准
- •Subject with other connective tissue diseases (e.g., systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis, polyarteritis nodosa, Sjogren's syndrome, mixed connective tissue disease, etc.) or ANCA associated vasculitis.
- •Diagnosed with polymyositis or IMNM.
- •Diagnosed with systemic, severe musculoskeletal disorder that unrelated to DM and will interfere with the investigator's assessment of the subject's muscle strength.
- •Subject who plans to start a physical therapy program during the trial.
- •Subject who has a medical history of New York Heart Association class III or IV congestive heart failure, clinically significant or uncontrolled unstable angina or myocardial infarction, cerebrovascular accident, or pulmonary embolism within 6 months prior to screening
- •Subject with impaired renal function (serum creatinine > 1.5 x ULN or creatinine clearance < 30 mL/min [Cockcroft-Gault formula]) at screening.
- •Any of following significant abnormalities in liver function at screening:
- •Serum alanine transaminase (ALT) or glutathione transaminase (AST) ≥ 3 x ULN, except when judged by the investigator to be due to DM;
- •Total bilirubin ≥ 1.5 x ULN;
- •Cirrhosis classification of Child-Pugh grade C.
- •Any of the following abnormalities at screening:
- •Hepatitis B-related tests: ① positive hepatitis B surface antigen (HBsAg); ② positive hepatitis B core antibody (HBcAb); ③ positive hepatitis B surface antibody (HBsAb) and no history of hepatitis B vaccination; ④ positive hepatitis B e antigen or hepatitis B e antibody;
- •Positive hepatitis C virus nucleic acid test (HCV-RNA);
- •Positive acquired immunodeficiency syndrome antibody (HIV-Ab);
- •Positive anti-syphilis spiral antibody (TP-Ab);
- •Other acute or chronic infections requiring treatment.
- •Absolute lymphocyte count < 0.5×109/L at screening
- •Subject who has a medical history of tuberculosis or those who deny a history of tuberculosis but has a positive gamma-interferon release test at screening.
- •Any other clinically significant clinical condition or laboratory tests abnormality that, in the judgment of the investigator, may affect the safety evaluation
- •Any malignant tumor other than the cured carcinoma in situ or basal cell carcinoma within 5 years before screening
- •Suspected allergic to the investigational drug or any of its excipients
- •Subject who had participated in other clinical studies (other than those not receiving interventions, such as observational study or questionnaires survey) within 3 months prior to screening, or who are participating in other experimental treatments.
- •Subject who requires to be administrated with higher dose of corticosteroids and/or immunesuppressant than the allowed maximum dose specified in the protocol (section 5.7.1)
- •Subject who had been treated by one or more of the following drugs during the corresponding time window prior to screening:
- •cyclophosphamide, rituximab within 12 months prior to screening;
- •belizumab, tetrasip within 24 weeks prior to screening;
- •intravenous immunoglobulin injections, baliximab, infliximab, adalimumab, tolimumab, JAK inhibitors within 12 weeks prior to screening;
- •Other monoclonal antibodies or other biological agents within 12 weeks or 5 half-lives [whichever is longer] prior to screening.
- •Currently pregnant, breastfeeding,or planning to become pregnant or not using reliable method to avoid pregnancy during study and within 3 months after the last study treatment
- •As determined by the investigator, any medical, psychiatric, or other condition or circumstance that is likely to negatively affect the reliability of the study data.
研究组 & 干预措施
Itolizumab Dose Level 1
Experimental
Itolizumab of 25 mg administered by intravenous infusion every 2 weeks for a total of 7 doses.
干预措施: Itolizumab (Drug)
Itolizumab Dose Level 2
Experimental
Itolizumab of 50 mg administered by intravenous infusion every 2 weeks for a total of 7 doses.
干预措施: Itolizumab (Drug)
Itolizumab Dose Level 3
Experimental
Itolizumab of 100 mg administered by intravenous infusion every 2 weeks for a total of 7 doses.
干预措施: Itolizumab (Drug)
结局指标
主要结局
Incidence of Treatment Emergent Adverse Events
时间窗: Study Week 20
Number of subjects with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) V5.0
次要结局
- IFN-γ(Study Week 16)
- ESR(Study Week 16)
- CRP(Study Week 16)
- Maximum serum concentration of Itolizumab, Cmax(Study Week 16)
- IL-6(Study Week 16)
- IL-2(Study Week 16)
- Proportion of patients achieving DOI(Study Week 16)
- TNF-α(Study Week 16)
- T cell subsets(Study Week 16)
- Proportion of patients achieving a TIS of ≥20(Study Week 16)
- Total Itolizumab exposure across time, AUC0-t(Study Week 16)
- Half life of Itolizumab, t1/2(Study Week 16)
- IgA(Study Week 16)
- Incidence of ADA(Study Week 16)
- Minimum serum concentration of Itolizumab, Cmin(Study Week 16)
- Time to maximum serum concentration of Itolizumab, Tmax(Study Week 16)
- IgM(Study Week 16)
- Serum ferritin(Study Week 16)
- IgG(Study Week 16)
- CD6 receptor expression levels(Study Week 16)
- Mean Change of Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) activity score(Study Week 16)
研究者
相似试验
尚未招募
1 期
Safety and Preliminary Clinical Activity of Itolizumab in ARDSAcute Respiratory Distress SyndromeNCT05978544Biotech Pharmaceutical Co., Ltd.38
招募中
1 期
Safety and Clinical Activity of Itolizumab in aGVHDAcute Graft Versus Host DiseaseNCT05823675Biotech Pharmaceutical Co., Ltd.44
进行中（未招募）
1 期
Atezolizumab for Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisNCT05515627Cedars-Sinai Medical Center24
招募中
1 期
Phase 1 Clinical Study of JMKX003142 TabletsSafety and TolerabilityNCT06079541Jemincare106
招募中
1 期
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid TumorsTriple Negative Breast CancerOvarian CancerMelanomaColorectal CancerNCT05746897Hefei TG ImmunoPharma Co., Ltd.38